AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Cancer-Related Pruritus: Mechanisms, Grading, and Treatment Strategies in Oncodermatology

Description

The talk reviewed cancer-related pruritus in oncodermatology, emphasizing that itch is common, underrecognized, and can be severe enough to disrupt cancer treatment. The speaker explained that itch in cancer patients may be perineoplastic, as in Hodgkin lymphoma or CTCL, or treatment-induced from chemotherapy, targeted therapies such as EGFR/BRAF/MEK inhibitors, and especially immunotherapies like immune checkpoint inhibitors. Mechanisms are often cytokine- and neuroimmune-driven rather than histamine-mediated, so antihistamines alone are usually insufficient. Management begins with identifying the cause, assessing disease status, reviewing medications, grading severity, and checking for other contributors such as xerosis, cholestasis, or uremia. For mild cases, emollients, topical corticosteroids, and sometimes sedating antihistamines can help; more significant disease often requires gabapentinoids, antidepressants, opioid modulators, narrowband UVB, or targeted biologics. The speaker highlighted IL-4/IL-13 blockade, especially dupilumab, and IL-31 inhibition as promising and generally safer than broad immunosuppression, while cautioning against prednisone and especially JAK inhibitors because they may impair anti-cancer immunity. Cases illustrated perineoplastic itch from Hodgkin lymphoma, EGFR-inhibitor acneiform pruritus, and checkpoint inhibitor–induced lichenoid dermatitis. Overall, effective care depends on early dermatology-oncology collaboration and using the most targeted therapy possible to control itch without compromising cancer outcomes.

View more

Conclusions

  • Pruritus is a common but often under-recognized problem in cancer patients that can substantially impair quality of life and even interrupt effective cancer therapy.
  • Cancer-related itch has both paraneoplastic and treatment-induced causes, so accurate diagnosis requires assessing the cancer type, treatment history, and any primary skin eruption or systemic contributor.
  • Histamine is often not the main driver of oncology-associated itch, making antihistamines alone frequently insufficient except for sedation or mild symptomatic relief.
  • Cytotoxic chemotherapy can provoke itch through xerosis, barrier damage, hypersensitivity, and direct toxic effects, with taxanes appearing particularly prone to cause clinically meaningful pruritus.
  • Targeted therapies, especially EGFR inhibitors, can cause highly pruritic acneiform eruptions, but the frequency and mechanism of itch vary widely across drug classes.
  • Immune checkpoint inhibitors commonly cause pruritus as part of cutaneous immune-related adverse events, and the risk is higher with combination immunotherapy than with monotherapy.
  • The emergence of cutaneous immune toxicity during checkpoint blockade often correlates with improved cancer outcomes and better survival, including when the manifestation is isolated pruritus.
  • Because some immunosuppressive treatments can blunt anti-tumor immunity, management should favor targeted approaches and avoid unnecessary systemic corticosteroids when possible.
  • Early, graded treatment escalation is important, with topical agents and emollients for mild disease and earlier use of targeted systemic therapies for more severe or refractory itch.
  • Biologic therapies such as IL-4/IL-13 blockade and IL-31 blockade appear promising and can control itch effectively without an obvious mortality penalty in observational data.
  • Dupilumab in particular showed high response rates for checkpoint-inhibitor-related skin toxicity and did not show an increased mortality signal, unlike systemic prednisone, which was associated with worse survival.
  • A multidisciplinary, multimodal approach involving dermatology and oncology is essential to control symptoms, preserve cancer treatment, and tailor therapy to the likely itch mechanism.
  • Di Salvo E., et al., Clin Mol Allergy. 2021 Jun 12;19(1):8.
  • Allegra A., et al., Biomedicines, 2020 Dec 22;9(1):2.
  • Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.#10.1016/b978-032303978-9.50028-9
  • Bracci L., et al. Cell Death Differ, 2014 Jan;21(1):15-25.
  • Lee et al., J Oncol Pharm Pract. 2022;28(3):233-239.
  • Maeda et al., Support Care Cancer 2021;29(4):313-322.
  • Wu J. et al., Dermatol Clin. 2018 Jul;36(3):315-324.
  • Lee, B., et al., Management of Melanoma.; 2017; 15–23.
  • Sullivan, R.J., et al. Nat Rev Drug Discov 21, 495–508 (2022).
  • Zhang, S., et al., JAAD, 2023.
  • Khattab, S., et al., medRxiv, 2025.01.07.25320156.
  • Khattab S. et al., Journal for ImmunoTherapy of Cancer, 2025.
  • Block BR, et al. JAMA Oncol. 2026;12(3):321-324.
  • Bartus, C.L., et al., Cutis, 2011 87 4, 169-72.
  • Bhattacharyya I., et al., Oral Surg, 2020 Nov;130(5):e301-e307.